These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31944570)

  • 1. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
    Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.
    Morikawa K; Kida H; Handa H; Inoue T; Miyazawa T; Mineshita M
    Thorac Cancer; 2020 May; 11(5):1339-1343. PubMed ID: 32142590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
    Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
    Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
    Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
    Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
    Gadgeel SM; Pennell NA; Fidler MJ; Halmos B; Bonomi P; Stevenson J; Schneider B; Sukari A; Ventimiglia J; Chen W; Galasso C; Wozniak A; Boerner J; Kalemkerian GP
    J Thorac Oncol; 2018 Sep; 13(9):1393-1399. PubMed ID: 29775808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
    Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].
    Sazuka M; Murano Y; Takada K; Nonaka K; Yamada H; Yamamoto H
    Nihon Ronen Igakkai Zasshi; 2018; 55(4):679-685. PubMed ID: 30542036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
    Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H
    BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
    Zaizen Y; Tokito T; Masuda K; Azuma K; Naito Y; Tsuneyoshi S; Sakazaki Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
    Intern Med; 2018 Dec; 57(23):3419-3422. PubMed ID: 29984774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report.
    Nozawa Y; Oka Y; Oosugi J; Takemura S
    Medicine (Baltimore); 2018 May; 97(19):e0718. PubMed ID: 29742733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
    Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.
    Zhang C; Jiang W; Li G; Li J; Kang Y; Yu X; Ma H; Feng Y
    Ann Palliat Med; 2021 Mar; 10(3):3510-3517. PubMed ID: 33849133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
    Fujita T; Hayama N; Kuroki T; Shiraishi Y; Amano H; Nakamura M; Hirano S; Aramaki N; Ichinose S; Shimizu S; Tabeta H; Nakamura S
    Thorac Cancer; 2019 Nov; 10(11):2179-2182. PubMed ID: 31512401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.